Association Between Early and Late Response in Eyes with Central or Hemiretinal Vein Occlusion Treated with Anti-VEGF Agents: SCORE2 Report 14: Secondary Analysis of the SCORE2 Clinical Trial

Podobne knjige/članki

• SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes with Central or Hemiretinal Vein Occlusion Managed with Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials
  od: Hendrick, Andrew, et al.
  Izdano: (2020)
• SCORE2 Report 5: Vision-Related Function in Patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
  od: Scott, Ingrid U., et al.
  Izdano: (2017)
• Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4
  od: Scott, Ingrid U., et al.
  Izdano: (2017)
• Month 24 Outcomes After Treatment Initiation With Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial
  od: Scott, Ingrid U., et al.
  Izdano: (2019)
• Ellipsoid Zone Defects in Retinal Vein Occlusion Correlates With Visual Acuity Prognosis: SCORE2 Report 14
  od: Etheridge, Tyler, et al.
  Izdano: (2021)